Document is current
Any future updates will be listed below
-
Authors
Rohden, Francieli
Ferreira, Pamela C. L. https://orcid.org/0000-0003-2134-9829
Bellaver, Bruna https://orcid.org/0000-0002-2212-3373
Ferrari-Souza, João Pedro https://orcid.org/0000-0003-2183-1551
Aguzzoli, Cristiano S. https://orcid.org/0000-0002-7378-3830
Soares, Carolina https://orcid.org/0000-0002-2338-4495
Abbas, Sarah
Zalzale, Hussein
Povala, Guilherme https://orcid.org/0000-0002-2023-6569
Lussier, Firoza Z.
Leffa, Douglas T.
Bauer-Negrini, Guilherme
Rahmouni, Nesrine
Tissot, Cécile https://orcid.org/0000-0003-2711-3833
Therriault, Joseph
Servaes, Stijn
Stevenson, Jenna
Benedet, Andrea L.
Ashton, Nicholas J.
Karikari, Thomas K. https://orcid.org/0000-0003-1422-4358
Tudorascu, Dana L.
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Zimmer, Eduardo R. https://orcid.org/0000-0002-5349-0053
Souza, Diogo
Rosa-Neto, Pedro https://orcid.org/0000-0001-9116-1376
Pascoal, Tharick A. https://orcid.org/0000-0001-9057-8014
-
Funding
Funding for this research was provided by:
Dr. Pascoal is supported by the NIA
- License Information
-
More Information
Article History
Received: 5 August 2024
Accepted: 4 June 2025
First Online: 1 July 2025
Competing interests
: Therriault has served as a paid consultant for the Neurotorium educational platform and Alzheon. Ashton received payment for lectures from Biogen, BioArctic, Eli-Lilly, and Quanterix. Karikari reported receiving grants from the National Institutes of Health (NIH) and personal fees from the University of Wisconsin–Madison and the University of Pennsylvania outside the submitted work. Additionally, he holds a patent for WO2020193500A1. Zetterberg received personal fees from multiple companies, including AbbVie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave. He also received personal fees for sponsored lectures from Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche outside the submitted work. Furthermore, Zetterberg is a cofounder of Brain Biomarker Solutions, part of the GU Ventures Incubator Program, outside the submitted work. Blennow has served as a consultant and on advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Eli Lilly and Co, Moleac Pte Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers. He has also served on data monitoring committees for Julius Clinical and Novartis, given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics. Additionally, he is a cofounder of Brain Biomarker Solutions, part of the GU Ventures Incubator Program, outside the submitted work. Zimmer served on the Scientific Advisory Board (SAB) of Novo Nordisk, serves on the SAB of Next Innovative Therapeutics (Nintx), and is a cofounder of MASIMA. Rosa-Neto served on the SAB of Novo Nordisk, Eisai, and Eli Lilly, and acted as a consultant for Eisai and Cerveau Radiopharmaceuticals. The remaining authors declare no competing interests.
